GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Psyence Biomedical Ltd (NAS:PBM) » Definitions » Intrinsic Value: Projected FCF

Psyence Biomedical (Psyence Biomedical) Intrinsic Value: Projected FCF : $0.00 (As of Apr. 28, 2024)


View and export this data going back to 2024. Start your Free Trial

What is Psyence Biomedical Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-04-28), Psyence Biomedical's Intrinsic Value: Projected FCF is $0.00. The stock price of Psyence Biomedical is $0.8589. Therefore, Psyence Biomedical's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Psyence Biomedical's Intrinsic Value: Projected FCF or its related term are showing as below:

PBM's Price-to-Projected-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 2.28
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Psyence Biomedical Intrinsic Value: Projected FCF Historical Data

The historical data trend for Psyence Biomedical's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Psyence Biomedical Intrinsic Value: Projected FCF Chart

Psyence Biomedical Annual Data
Trend Mar21 Mar22 Mar23
Intrinsic Value: Projected FCF
- - -

Psyence Biomedical Semi-Annual Data
Mar21 Mar22 Mar23
Intrinsic Value: Projected FCF - - -

Competitive Comparison of Psyence Biomedical's Intrinsic Value: Projected FCF

For the Biotechnology subindustry, Psyence Biomedical's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Psyence Biomedical's Price-to-Projected-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Psyence Biomedical's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Psyence Biomedical's Price-to-Projected-FCF falls into.



Psyence Biomedical Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)



Psyence Biomedical  (NAS:PBM) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Psyence Biomedical's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=0.8589/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Psyence Biomedical Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Psyence Biomedical's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Psyence Biomedical (Psyence Biomedical) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
121 Richmond Street West, Penthouse Suite 1300, Toronto, ON, CAN, M5H 2K1
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed ISO22000 facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

Psyence Biomedical (Psyence Biomedical) Headlines